Immuno-Biological Laboratories (IBL) Revenue

Medical Equipment Manufacturing • Fujioka City, Gunma, Japan • 1-10 Employees

Immuno-Biological Laboratories (IBL) revenue & valuation

Annual revenue	$598,885
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues	$2,000,000
Total funding	$12,200,000

Key Contacts at Immuno-Biological Laboratories (IBL)

Ayano Enya

Executive Director, International Business Development

Masahiro Maeda

Director

Company overview

Headquarters	1091-1, Naka, Aza-Higashida, Fujioka, Gumma 375-0005, JP
Phone number	+81272129701
Website	ibl-japan.co.jp
NAICS	3391
SIC	283
Keywords	Antibody, Aging, Kidney Disease, Elisa, Inflammatory Disease, Neurodegenerative, Glucose/Lipid Metabolism
Founded	1982
Employees	1-10
Socials

About Immuno-Biological Laboratories (IBL)

IBL originates from Japan who is an Antibody and ELISA manufacturer for worldwide use. The company founder and corporate President of IBL, Mr. Tsutomu Seito is one of the pioneers of Monoclonal antibody. Mr. Seito's spirit and passion, "Supplying valuable antibodies to save people fighting against diseases all over the world" are reflected our services and products as our corporate philosophy since the establishment of the company. <History of IBL> IBL is constantly improving in antibody development since the establishment in 1982. The total number of antigens used in antibody development is over 5,000 and IBL has provided more than 10,000 contract services. <IBL Brand> We have unique in-house developed products that are supplied worldwide. The total number of IBL Products is around 500 with more than 120 ELISA products and more than over 350 antibodies. <Global Supply Network> IBL products are distributed through a network of valued international distributors in more than 80 countries in the major markets as well. <Japan Quality> IBL is maintaining the ISO13485 certification since 2009. All our antibodies and ELISA products are manufactured and controlled in-house at our head office and main laboratory located in Japan. We are proud and confident in the quality of our products and services. <Main Area> * Inflammatory Disease (Cancers, Arthritis, Hepatitis etc.) * Kidney Diseases (CKD, AKI, IgA Nephropathy(IGAN), Hypertension etc.) * Aging, Neurodegenerative (Alzheimer's disease (AD) etc.) * Glucose/Lipid Metabolism (Diabetes, Hyperlipidemia, Cardiovascular Events etc. )

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Entry

Intern

Employees by Department

Immuno-Biological Laboratories (IBL) has 4 employees across 2 departments.

Departments

Number of employees

Funding Data

Explore Immuno-Biological Laboratories (IBL)'s funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2017-01-01	16	$12,200,000

Funding Insights

$12,200,000

Total funding amount

$12,200,000

Most recent funding amount

Number of funding rounds

Immuno-Biological Laboratories (IBL) Tech Stack

Discover the technologies and tools that power Immuno-Biological Laboratories (IBL)'s digital infrastructure, from frameworks to analytics platforms.

SWFObject

Miscellaneous

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

Nginx

Reverse proxies

Slick

JavaScript libraries

HSTS

Security

FancyBox

JavaScript libraries

Font Awesome

Font scripts

Google Analytics

Analytics

YouTube

Video players

Bootstrap

UI frameworks

RSS

Miscellaneous

Frequently asked questions

Immuno-Biological Laboratories (IBL) is located in Fujioka City, Gunma, JP.

You can reach Immuno-Biological Laboratories (IBL) at +81272129701.

Immuno-Biological Laboratories (IBL) generates an estimated annual revenue of $598,885. This revenue figure reflects the company's market position and business performance in its industry.

Immuno-Biological Laboratories (IBL) has an estimated valuation of $2,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Immuno-Biological Laboratories (IBL) was founded in 1982, making it 44 years old. The company has established itself as a significant player in its industry over this time.

Immuno-Biological Laboratories (IBL) has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Immuno-Biological Laboratories (IBL) has raised a total of $12,200,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Immuno-Biological Laboratories (IBL)

Ayano Enya

Executive Director, International Business Development

Masahiro Maeda

Director

4.8

40,000 users